Cannabis Law Report

OCTOBER 5, 2021

Media: media@mymd.com. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

MMJ Recs

JULY 3, 2024

From the pressures of work and personal relationships to the constant bombardment of information on social media and the news, many individuals find themselves struggling to cope with these challenges. The prevalence of anxiety disorders and stress-related conditions has risen significantly in recent decades.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

JUNE 7, 2021

Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

SEPTEMBER 22, 2021

At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Project CBD

FEBRUARY 28, 2023

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: www.fda.gov/media/131878/download. US Food and Drug Administration website. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 7, 2021

Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JANUARY 6, 2022

Scott will work closely with the management team to further develop the company’s internal and external communications with a focus on strategy, branding, social media presence and investor communications. Anebulo Pharmaceuticals, Inc. Scott Anderson. Head of Investor Relations and Public Relations. 858) 229-7063. scott@anebulo.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JULY 6, 2021

Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

MMJ Recs

DECEMBER 22, 2023

Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. Media Portrayal and Its Role in Shaping Medical Cannabis Attitudes Media plays a pivotal role in shaping public perception, and the portrayal of medical cannabis is no exception.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Info

OCTOBER 11, 2019

Dementia is a catch-all term for the conditions that cause declining memory and thinking skills, including Alzheimer’s, Parkinson’s and vascular dementia. In the Australian clinical study, cannabinoids will be extracted and delivered in a mouth spray, making it easier to be administered to the elderly. Cannabis research in the U.S.

Treatment 45

Treatment Clinical Trials Cannabinoids Cannabis 45

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. Minister for Industry and Skills David Pisoni published a media release to mark the occasion, entitled South Australia welcomes cannabis industry leaders.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

The Cannigma

JUNE 24, 2021

While many health conditions can be treated with more traditional pharmaceuticals, plant-based products may be a safer and healthier option – or at least a safe health supplement. By interacting with the receptors of the ECS, cannabis modulates the bodily functions that cause or exacerbate health conditions.

CBD 78

CBD Microdosing Edibles Sleep 78

Cannabis Law Report

SEPTEMBER 24, 2019

Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. All investor and media enquiries. media enquiries. media enquiries. What about other medical cannabis products? “The

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible. The cannabis research problem.

Research and Development 112

Research and Development Data THC Clinical Trials 112

Cannabis Law Report

JULY 24, 2019

Curaleaf CURLF, -7.27% is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” the FDA wrote. Mental conditions like anxiety, depression, and PTSD.”.

CBD 51

CBD Tincture Pets Chronic Pain 51

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Marijuana Preferred Over Pain Pills. A broad-based study conducted by Florida International University looked at information from the National Survey on Drug Use and Health.

Marijuana 88

Marijuana Patients Clinical Trials Data 88

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinical trials before they can conclude certain products as GRAS. “To

CBD 33

CBD Clinical Trials Safety Media 33

CannaMD

MARCH 8, 2021

Which begs the question: Why is it okay for Big Pharma to profit from high-potency THC drugs, while Florida patients can’t use high-potency THC medical marijuana to treat documented health conditions under a physician’s care? Instead of restricting free speech, the FTC recommends parents practice “media literacy.”. How to learn more.

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

JULY 12, 2019

The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

JANUARY 11, 2019

However, we firmly disagree that the referenced clinical trials are in fact “substantial,” as the trials were extremely limited in scope, and funding and the publication of these trials were limited. 9] While that portion of the statement provoked a few breathless media reports, it was old news.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT . 831-429-6362 ext 303.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

The Cannigma

MAY 19, 2021

This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. The future of weed legalization in Japan.

Law 140

Law Legalization Clinical Trials CBD 140

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Email: alexander.speiser@eleusisltd.com.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JANUARY 12, 2022

. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. Media Contact. In addition, Gb Sciences has 12 U.S. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. The Independent Expert Panel was established to undertake a systematic literature review of the roles of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. Different strains for different conditions. Media event date: 27 August 2019.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Conclusions. Background.

Research and Development 52

Research and Development Medicine Access Media 52

FloridaMarijuana.net

OCTOBER 19, 2018

Depression can be situational, but Clinical Depression, which comes and goes and/or lasts for more than a few days, is a chemical imbalance within the central nervous system. Depression can make these conditions worse and vice versa. The NIMH states that women are often more affected by Depression than men.

Marijuana 189

Marijuana Research and Development Patients Clinical Trials 189

Cannabis Law Report

AUGUST 3, 2021

There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Media Contact : John Kanakis. The Neo Exchange Inc.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Delic is focused on bringing psychedelic wellness to the mainstream.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

MARCH 29, 2020

o Technology powered research: Virtual clinical trials and other accelerated technologies that mix the potential of new technologies with cannabis to create research insights quickly and more accurately, are being classified as Cannabis 3.0, triggering new innovations and improved data quality through better user experiences.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

The Cannigma

APRIL 8, 2021

The doctor diagnoses the condition and chooses a specific medicine. That there’s not enough information about, there’s not enough clinical trials, and there’s not enough this and that. They get pumped out through the media and everybody’s talking about how dangerous it is.

Medicine 112

Medicine Cannabinoids Cannabis THC 112

Puff Puff Post

SEPTEMBER 16, 2019

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.

Programs 108

Programs Research and Development Education Treatment 108